Generex (GNBT):
Generex said this morning that they had now achieved 75% of the required number of per-protocol completers in its Phase III trial of Oral-lyn. The company noted that early results may suggest that the use of Oral-lyn will support a non-inferiority claim relative to standard of care injectable insulin. The company reiterated that patients taking Oral-lyn on average showed no weight gain and an actual decrease in Body Mass Index (BMI). » Read more: Daily Pharma Watch
XOMA Ltd (XOMA):
This morning shares of Xoma were halted pending the announcement of results from eye study for their lead drug XOMA-052. The company released data from a small open label study that only included 7 patients. The company said that the patients in the study that were suffering from vision-threatening exacerbations from Behcet’s disease showed a rapid reduction of intraocular inflammation and improved visual acuity. » Read more: Daily Pharma Watch
© 2010 GekkoWire · Proudly powered by WordPress & Green Park 2 by Cordobo.
Valid XHTML 1.0 Transitional | Valid CSS 3
Twitter